Cutting Edge Molecular Therapy for Acute Myeloid Leukemia

被引:7
作者
Miyamoto, Kenichi [1 ]
Minami, Yosuke [1 ]
机构
[1] Natl Canc Ctr Hosp East, Dept Hematol, Kashiwa, Chiba 2778577, Japan
关键词
acute myeloid leukemia; FMS-like tyrosine kinase 3; isocitrate dehydrogenase; immune checkpoint inhibitor; chimeric antigen receptor; CONVENTIONAL CARE REGIMENS; PHASE-II TRIAL; TERM-FOLLOW-UP; T-CELL; COMPLEX KARYOTYPE; NEDD8-ACTIVATING ENZYME; CYTOSINE-ARABINOSIDE; OLDER PATIENTS; ADULT PATIENTS; MUTANT LEVEL;
D O I
10.3390/ijms21145114
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recently, whole exome sequencing for acute myeloid leukemia (AML) has been performed by a next-generation sequencer in several studies. It has been revealed that a few gene mutations are identified per AML patient. Some of these mutations are actionable mutations that affect the response to an approved targeted treatment that is available for off-label treatment or that is available in clinical trials. The era of precision medicine for AML has arrived, and it is extremely important to detect actionable mutations relevant to treatment decision-making. However, the percentage of actionable mutations found in AML is about 50% at present, and therapeutic development is also needed for AML patients without actionable mutations. In contrast, the newly approved drugs are less toxic than conventional intensive chemotherapy and can be combined with low-intensity treatments. These combination therapies can contribute to the improvement of prognosis, especially in elderly AML patients who account for more than half of all AML patients. Thus, the treatment strategy for leukemia is changing drastically and showing rapid progress. In this review, we present the latest information regarding the recent development of treatment for AML.
引用
收藏
页码:1 / 23
页数:23
相关论文
共 125 条
[1]   The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia [J].
Allen, C. ;
Hills, R. K. ;
Lamb, K. ;
Evans, C. ;
Tinsley, S. ;
Sellar, R. ;
O'Brien, M. ;
Yin, J. L. ;
Burnett, A. K. ;
Linch, D. C. ;
Gale, R. E. .
LEUKEMIA, 2013, 27 (09) :1891-1901
[2]   Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial [J].
Amadori, Sergio ;
Suciu, Stefan ;
Selleslag, Dominik ;
Aversa, Franco ;
Gaidano, Gianluca ;
Musso, Maurizio ;
Annino, Luciana ;
Venditti, Adriano ;
Voso, Maria Teresa ;
Mazzone, Carla ;
Magro, Domenico ;
De Fabritiis, Paolo ;
Muus, Petra ;
Alimena, Giuliana ;
Mancini, Marco ;
Hagemeijer, Anne ;
Paoloni, Francesca ;
Vignetti, Marco ;
Fazi, Paola ;
Meert, Liv ;
Ramadan, Safaa Mahmoud ;
Willemze, Roel ;
de Witte, Theo ;
Baron, Frederic .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (09) :972-+
[3]  
[Anonymous], 2017, BLOOD S1
[4]  
[Anonymous], 2018, J CLIN ONCOL S
[5]  
[Anonymous], BLOOD
[6]  
[Anonymous], 2018, BLOOD S1, DOI DOI 10.1182/BLOOD-2018-99-112614
[7]   PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].
Ansell, Stephen M. ;
Lesokhin, Alexander M. ;
Borrello, Ivan ;
Halwani, Ahmad ;
Scott, Emma C. ;
Gutierrez, Martin ;
Schuster, Stephen J. ;
Millenson, Michael M. ;
Cattry, Deepika ;
Freeman, Gordon J. ;
Rodig, Scott J. ;
Chapuy, Bjoern ;
Ligon, Azra H. ;
Zhu, Lili ;
Grosso, Joseph F. ;
Kim, Su Young ;
Timmerman, John M. ;
Shipp, Margaret A. ;
Armand, Philippe .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319
[8]   Age and acute myeloid leukemia [J].
Appelbaum, FR ;
Gundacker, H ;
Head, DR ;
Slovak, ML ;
Willman, CL ;
Godwin, JE ;
Anderson, JE ;
Petersdorf, SH .
BLOOD, 2006, 107 (09) :3481-3485
[9]   Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia [J].
Battipaglia, Giorgia ;
Ruggeri, Annalisa ;
Massoud, Radwan ;
El Cheikh, Jean ;
Jestin, Matthieu ;
Antar, Ahmad ;
Ahmed, Syed Osman ;
Rasheed, Walid ;
Shaheen, Marwan ;
Belhocine, Ramdane ;
Brissot, Eolia ;
Dulery, Remy ;
Eder, Sandra ;
Giannotti, Federica ;
Isnard, Francoise ;
Lapusan, Simona ;
Rubio, Marie-Therese ;
Vekhoff, Anne ;
Aljurf, Mahmoud ;
Legrand, Ollivier ;
Mohty, Mohamad ;
Bazarbachi, Ali .
CANCER, 2017, 123 (15) :2867-2874
[10]   MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L [J].
Bernt, Kathrin M. ;
Zhu, Nan ;
Sinha, Amit U. ;
Vempati, Sridhar ;
Faber, Joerg ;
Krivtsov, Andrei V. ;
Feng, Zhaohui ;
Punt, Natalie ;
Daigle, Amanda ;
Bullinger, Lars ;
Pollock, Roy M. ;
Richon, Victoria M. ;
Kung, Andrew L. ;
Armstrong, Scott A. .
CANCER CELL, 2011, 20 (01) :66-78